Abstract: The present disclosure provides a method for producing a cell-culturing polyvinyl alcohol-based nanofiber structure, the method comprising: electrospinning an electrospun solution to form a nanofiber mat, wherein the electrospun solution contains polyvinyl alcohol (PVA), polyacrylic acid (PA) and glutaraldehyde (GA); crosslinking the nanofiber mat via a hydrochloric acid (HCl) vapor treatment; and treating the crosslinked nanofiber mat with dimethylformamide (DMF) solvent to crystallize the nanofiber mat.

Abstract: The present disclosure provides a method for producing a cell-culturing polyvinyl alcohol-based nanofiber structure, the method comprising: electrospinning an electrospun solution to form a nanofiber mat, wherein the electrospun solution contains polyvinyl alcohol (PVA), polyacrylic acid (PA) and glutaraldehyde (GA); crosslinking the nanofiber mat via a hydrochloric acid (HCl) vapor treatment; and treating the crosslinked nanofiber mat with dimethylformamide (DMF) solvent to crystallize the nanofiber mat.

Abstract: The present invention relates to a patch comprising a high content of rivastigmine per unit area, which can be continuously administered for a long time. The rivastigmine patch according to the present invention is capable of continuous release of rivastigmine for a long period of time, preferably 3 days, more preferably 4 days or more after attachment, and has excellent physical and chemical stability.

Abstract: The present invention relates to a patch comprising a high content of rivastigmine per unit area, which can be continuously administered for a long time. The rivastigmine patch according to the present invention is capable of continuous release of rivastigmine for a long period of time, preferably 3 days, more preferably 4 days or more after attachment, and has excellent physical and chemical stability.

Abstract: The present invention relates to a method of manufacturing a polycaprolactone nanostructure with improved cell adhesive ability containing fucoidan according to the present invention comprises dissolving fucoidan in glacial acetic acid as a solvent to obtain fucoidan-glacial acetic acid solution, mixing polycaprolactone with the fucoidan-glacial acetic acid solution to obtain a polycaprolactone-mixed solution, and manufacturing a nanostructure from the polycaprolactone-mixed solution by an electrospinning method. Therefore, a polycaprolactone nanostructure with improved cell adhesive ability containing fucoidan manufactured by the method according to the present invention exhibits characteristics of preventing fucoidan from being released from nanofibers by uniformly distributing fucoidan in the polycaprolactone nanostructure.

Abstract: The present invention relates to a method of manufacturing a polycaprolactone nanostructure with improved cell adhesive ability containing fucoidan according to the present invention comprises dissolving fucoidan in glacial acetic acid as a solvent to obtain fucoidan-glacial acetic acid solution, mixing polycaprolactone with the fucoidan-glacial acetic acid solution to obtain a polycaprolactone-mixed solution, and manufacturing a nanostructure from the polycaprolactone-mixed solution by an electrospinning method. Therefore, a polycaprolactone nanostructure with improved cell adhesive ability containing fucoidan manufactured by the method according to the present invention exhibits characteristics of preventing fucoidan from being released from nanofibers by uniformly distributing fucoidan in the polycaprolactone nanostructure.

Abstract: A method for preparing a transdermal absorption composition includes mixing rotigotine and an antioxidant at a weight ratio of 1:0.0001 to 0.1. A transdermal therapeutic system includes a substrate and a drug-containing adhesive layer disposed on the substrate and including an antioxidant at a weight ratio of 1:0.0001 to 0.1. The method and system of the present invention suppress the crystallization of rotigotine as well as the generation of related substances, thereby increasing the long-term storage stability of a therapeutic product containing rotigotine or related substances.

Abstract: A method for preparing a transdermal absorption composition includes mixing rotigotine and an antioxidant at a weight ratio of 1:0.0001 to 0.1. A transdermal therapeutic system includes a substrate and a drug-containing adhesive layer disposed on the substrate and including an antioxidant at a weight ratio of 1:0.0001 to 0.1. The method and system of the present invention suppress the crystallization of rotigotine as well as the generation of related substances, thereby increasing the long-term storage stability of a therapeutic product containing rotigotine or related substances.

Abstract: Provided is a transdermal delivery system (for example, in the form of a patch) having a double-layer structure including a drug-containing matrix layer and an adhesive layer, wherein the drug-containing matrix layer is obtained by completely dissolving donepezil using a certain polymer and then formulating along with an adhesive; and a process for preparing the same. The transdermal delivery system according to the present invention does not show any crystallization of donepezil in the formulation, can release donepezil at a uniform rate for a long time, and can inhibit the release dumping phenomenon that occurs in a transdermal delivery system having a single-layer structure.

Abstract: The present invention relates to a rivastigmine-containing patch having improved storage stability and proper release property.

Abstract: A transdermal composition comprising tolterodine having improved storage stability is disclosed. The transdermal composition comprising tolterodine contains an antioxidant to stabilize tolterodine and can be stored for a long period of time.

Abstract: The present invention provides a rivastigmine medicine having improved stability. The invention also provides a method, for packing pharmaceutical medicines containing rivastigmine, capable of improving stability.

Abstract: A method for preventing the precipitation of rotigotine crystals, including a step of mixing rotigotine and one or more crystallization prevention agents selected from the group consisting of fatty alcohols, fatty acids, fatty acid esters, fatty acid amides, and the derivatives thereof, and to a transdermally absorbable preparation that includes rotigotine and crystallization prevention agents.

Abstract: Exemplary embodiments of the present invention relate to a method for preparing a preparation for percutaneous absorption, which includes rotigotine as an active ingredient, and more specifically, to a method for preparing a preparation for percutaneous absorption including mixing rotigotine and an ethylene-vinyl acetate adhesive so as to have a weight ratio of 1:(0.1 to 20), a preparation for percutaneous absorption manufactured by the method, and a percutaneous treatment system. The preparation and the system may prevent separation of the rotigotine, thereby increasing long-term storage stability, and effectively release the rotigotine, and thus can be effectively applied to preparing patch medication containing the rotigotine.

Abstract: Provided is a transdermal delivery system (for example, in the form of a patch) having a double-layer structure including a drug-containing matrix layer and an adhesive layer, wherein the drug-containing matrix layer is obtained by completely dissolving donepezil using a certain polymer and then formulating along with an adhesive; and a process for preparing the same. The transdermal delivery system according to the present invention does not show any crystallization of donepezil in the formulation, can release donepezil at a uniform rate for a long time, and can inhibit the release dumping phenomenon that occurs in a transdermal delivery system having a single-layer structure.

Abstract: Disclosed is a composition for transdermal administration containing tolterodine. The composition comprises lidocaine or a pharmaceutically acceptable salt thereof to achieve enhanced skin penetration. The composition enhances the skin penetration of tolterodine. Therefore, a successful commercial application of a tolterodine-containing transdermal preparation based on the composition can be expected.

Abstract: The present invention relates to a rivastigmine-containing patch having improved storage stability and proper release property.

Abstract: Disclosed is a composition for transdermal administration containing tolterodine. The composition comprises lidocaine or a pharmaceutically acceptable salt thereof to achieve enhanced skin penetration. The composition enhances the skin penetration of tolterodine. Therefore, a successful commercial application of a tolterodine-containing transdermal preparation based on the composition can be expected.

Abstract: Disclosed is a composition for transdermal administration containing tolterodine. The composition comprises at least one essential oil as an abirritant to minimize skin irritation caused by tolterodine. The composition relieves skin irritation caused by tolterodine. Therefore, a successful commercial application of a tolterodine-containing transdermal preparation based on the composition can be expected.

Abstract: A transdermal composition comprising tolterodine having improved storage stability is disclosed. The transdermal composition comprising tolterodine contains an antioxidant to stabilize tolterodine and can be stored for a long period of time.